Humana (NYSE:HUM) Stock Price Down 2.9% – Should You Sell?

Humana Inc. (NYSE:HUM)’s share price fell 2.9% on Monday . The stock traded as low as $288.00 and last traded at $286.51. 153,686 shares changed hands during mid-day trading, a decline of 91% from the average session volume of 1,746,191 shares. The stock had previously closed at $295.04.

Analysts Set New Price Targets

HUM has been the subject of several research reports. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $290.00 price target on shares of Humana in a research note on Wednesday, February 12th. JPMorgan Chase & Co. cut their target price on shares of Humana from $257.00 to $256.00 and set a “neutral” rating for the company in a research report on Tuesday, February 18th. Mizuho upped their price target on shares of Humana from $305.00 to $316.00 and gave the company an “outperform” rating in a report on Wednesday, April 9th. Royal Bank of Canada reissued an “outperform” rating and set a $283.00 price objective on shares of Humana in a research note on Wednesday, February 12th. Finally, Truist Financial upped their target price on Humana from $290.00 to $325.00 and gave the company a “hold” rating in a research note on Friday, April 11th. Seventeen equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $284.90.

Humana Price Performance

The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. The company’s fifty day moving average is $265.57 and its 200 day moving average is $270.22. The stock has a market cap of $34.61 billion, a PE ratio of 28.82, a price-to-earnings-growth ratio of 2.05 and a beta of 0.62.

Humana (NYSE:HUM) last announced its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. As a group, sell-side analysts anticipate that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be issued a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a yield of 1.23%. The ex-dividend date is Friday, March 28th. Humana’s dividend payout ratio is presently 35.58%.

Institutional Trading of Humana

A number of hedge funds have recently made changes to their positions in the company. Dodge & Cox grew its holdings in Humana by 106.7% during the 4th quarter. Dodge & Cox now owns 10,198,040 shares of the insurance provider’s stock valued at $2,587,345,000 after purchasing an additional 5,264,045 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Humana by 15.8% during the fourth quarter. Vanguard Group Inc. now owns 12,829,210 shares of the insurance provider’s stock valued at $3,254,899,000 after acquiring an additional 1,751,857 shares in the last quarter. Norges Bank acquired a new position in shares of Humana in the fourth quarter worth about $416,202,000. Pzena Investment Management LLC boosted its holdings in Humana by 44.0% in the fourth quarter. Pzena Investment Management LLC now owns 3,609,382 shares of the insurance provider’s stock valued at $915,736,000 after purchasing an additional 1,103,132 shares during the last quarter. Finally, Boston Partners boosted its holdings in Humana by 435.8% in the fourth quarter. Boston Partners now owns 1,098,702 shares of the insurance provider’s stock valued at $279,236,000 after purchasing an additional 893,637 shares during the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.